Open AccessCarfilzomib Combined With Thalidomide and Low‐dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma: 8 vs 4 Induction Cycles; the Carthadex Trial
Author(s) -
Wester Ruth,
Zweegman Sonja,
Holt Bronno,
Kersten Marie José,
Vellenga Edo,
MarwijkKooy Marinus,
Asselbergs Emelie,
Weerdt Okke,
Minnema Monique C.,
Lonergan Sarah,
Palumbo Antonio,
Broijl Annemiek,
Sonneveld Pieter
Publication year - 2020
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/hs9.0000000000000370
Subject(s) - carfilzomib , bortezomib , medicine , multiple myeloma , thalidomide , dexamethasone , proteasome inhibitor , lenalidomide , oncology , discontinuation , ixazomib , pharmacology